

THE USE OF CELL THERAPIES FOR AUTOIMMUNE DISEASES: CAR-T FROM BIOLOGY TO CLINICAL APPLICATION

October 16 – 17, 2025, Paris, France

COURSE OVERVIEW

The 1.5-day in-person Cell Therapies for Autoimmune Diseases: CAR-T from Biology to Clinical Application Course is designed for clinicians, clinical scientists, medical students, and researchers dedicated to translating CAR-T cell therapies from research to clinical practice. Led by pioneers in CAR-T cell development and application the course focuses on the application of CAR-T cell therapies for autoimmune diseases, including severe lupus, myositis, systemic sclerosis, juvenile dermatomyositis, multiple sclerosis, and more.

WHO IT IS DESIGNED FOR

- Clinical researchers, clinicians and physicians engaging in the translation of CAR-T cell for clinical applications
- Medical students aiming to broaden their knowledge and advancement of CAR-T cell therapy

DELIVERY METHOD

-  In-person 1.5-day course
-  October 16 – 17, 2025
Verniquet Amphitheatre
-  Muséum national d'Histoire naturelle
57 rue Cuvier, 75005 Paris, France

International Society
ISCT
Cell & Gene Therapy®

EBAH 
European Board for Accreditation in Hematology



10 Hours of Continuing Education (CE) / CMLE Hours

THANK YOU TO OUR SPONSORS



THE USE OF CELL THERAPIES FOR AUTOIMMUNE DISEASES: CAR-T FROM BIOLOGY TO CLINICAL APPLICATION



DAY 1: October 16, 2025

11:15 - 12:00 REGISTRATION
Arrival Coffee

1ST SESSION: INTRODUCTION TO CAR-T IN AUTOIMMUNE DISEASES

Chairs:

Dominique Farge, MD, PhD

ISCT Regional Vice-President, Europe
Internal Medicine, St Louis Hospital, Paris-Cité University, France

Fermin Sanchez-Guijo, MD, PhD

ISCT Immediate Past Regional Vice-President, Europe
Department of Medicine, University of Salamanca, Department of Hematology University Hospital Salamanca, Spain

12:00 - 12:30 OVERVIEW OF CAR-T CELL THERAPY: PAST, PRESENT AND FUTURE OF CAR-T

Speaker: **Bruce Levine, PhD**

Barbara and Edward Netter Professor, University of Pennsylvania, United States

12:30 - 13:00 B CELL AND AUTOIMMUNITY

Speaker: **Karin Tarte, Pharm D, PhD**

Director UMR U1236-MOBIDIC, Head of Honeycomb Research Team, Head of the Immunology Lab at Rennes University Hospital, Head of Rennes Immunomonitoring Platform (SITI), Medical School of Rennes, France

13:00 - 13:30 TARGETED BIOLOGICAL THERAPIES IN AUTOIMMUNE DISEASES

Speaker: **Tobias Alexander, MD**

Senior Physician, Head of the Rheumatology Outpatient Clinic, Charité – Berlin University Medicine Germany

13:30 - 14:00 CAR-T IN AUTOIMMUNE DISEASES: FROM CONCEPT TO REALITY

Speaker: **Georg Schett, MD, PhD**

Vice President of Research & Head of Department of Internal Medicine, University of Erlangen–Nuremberg Germany

14:00 - 14:20 INTERACTIVE PANEL DISCUSSION

14:20 - 15:00 BREAK

2ND SESSION: THE SUCCESS STORY: CAR-T CELL THERAPY IN SLE

Chairs:

Georg Schett, MD, PhD

Vice President of Research & Head of Department of Internal Medicine, University of Erlangen–Nuremberg, Germany

Franco Locatelli, MD, PhD

Director of the Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Italy

15:00 - 15:25 SLE TREATMENT AND PROGNOSIS

Speaker: **Andrea Doria, MD, PhD**

Head of the Rheumatology Unit, Department of Medicine, Padova University School of Medicine, Italy

15:25 - 15:50 CAR-T ANTI-CD19 IN SEVERE LUPUS

Speaker: **Fabian Muller, MD**

Head of Research Group in Molecular Immunotherapy University Hospital Erlangen, Germany

15:50 - 16:15 CAR-T REGS IN LUPUS

Speaker: **Raffaella Greco, MD**

Senior Hematologist, Hematology & Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Italy

16:15 - 16:40 CONSIDERATIONS ON LYMPHODEPLETION FOR AUTOIMMUNE DISEASE PATIENTS

Speaker: **Jaap Jan Boelens, MD, PhD**

Chief Pediatric-Oncologist, Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, United States

16:40 - 17:05 IMMUNE MONITORING AND IMMUNE RECONSTITUTION AFTER CAR-T INJECTION IN AUTOIMMUNE DISEASES

Speaker: **Andreas Mackensen, MD**

Deputy Director of the CCC Erlangen-EMN, Director of the Medical Clinic 5 (Hematology and Internal Oncology), University Hospital Erlangen, Germany

17:05 - 17:35 INTERACTIVE PANEL DISCUSSION

THE USE OF CELL THERAPIES FOR AUTOIMMUNE DISEASES: CAR-T FROM BIOLOGY TO CLINICAL APPLICATION



DAY 2: October 17, 2025

3RD SESSION: CAR-T CELLS IN OTHER RHEUMATIC DISEASES: EARLY CLINICAL EXPERIENCES AND PATIENT SELECTION

Chairs:

Andreas Mackensen, MD

Deputy Director of the CCC Erlangen-EMN, Director of the Medical Clinic 5 (Hematology and Internal Oncology), University Hospital Erlangen, Germany

Oliver Distler, MD, PhD

Director of the Department of Rheumatology, University Hospital Zurich, Switzerland

08:45 - 09:00 IS THERE A PLACE FOR CAR-T IN RHEUMATIC ARTHRITIS

Speaker: **Doron Rimar, MD**

Senior Physician, Director of the Rheumatology Daycare Center, Bnai Zion Medical Center, Israel

09:00 - 09:15 CAR-T FOR MYOSITIS & INTERSTITIAL LUNG DISEASE

Speaker: **Jörg Henes, MD, PhD**

Head of the Rheumatology Department, Senior Physician of the Department of Medical Clinic II University of Tübingen, Germany

09:15 - 09:30 CAR-T IN SCLERODERMA

Speaker: **Alain Lescoat, MD, PhD**

Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, France

09:30 - 09:45 CAR-T IN JUVENILE DERMATOMYOSITIS

Speaker: **Franco Locatelli, MD, PhD**

Director of the Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Italy

09:45 - 10:00 PATIENT SELECTION AND ADWP EBMT GUIDELINES FOR CLINICAL PRACTICES

Speaker: **Dominique Farge, MD, PhD**

ISCT Regional Vice-President, Europe Internal Medicine, St Louis Hospital, Paris-Cité University, France

10:00 - 10:30 INTERACTIVE PANEL DISCUSSION

10:30 - 11:00 BREAK

4TH SESSION: CAR-T IN NEUROLOGICAL AUTOIMMUNE DISEASES

Chairs:

Paolo Muraro, MD, PhD

Neuroimmunology and Neurology, Department of Brain Sciences – Faculty of Medicine, Imperial College, London

Dimitrios Mougiakakos, MD, PhD

Clinical Director, Center for Internal Medicine, Department of Hematology, Oncology and Cell Therapy, University Hospital Magdeburg

11:00 - 11:25 B CELL TARGETED THERAPY IN INFLAMMATORY AUTOIMMUNE DISEASES OF THE CNS

Speaker: **Aiden Haghikia, MD, PhD**

Clinical Director, Department of Neurology, University Hospital Magdeburg, Germany

11:25 - 11:50 RESETTING THE IMMUNE REPERTOIRE IN NEUROLOGICAL AUTOIMMUNE DISEASES

Speaker: **Paolo Muraro, MD, PhD**

Neuroimmunology and Neurology, Department of Brain Sciences – Faculty of Medicine, Imperial College London, United Kingdom

11:50 - 12:15 CAR-T IN MULTIPLE SCLEROSIS

Speaker: **Christoph Heesen, MD, PhD**

Clinical and Rehabilitative MS Research, Head of Multiple Sclerosis Day Hospital, University Medical Center Hamburg-Eppendorf, Germany

12:15 - 12:40 CAR-T IN MYASTHENIA GRAVIS, MNO AND STIFF SYNDROME

Speaker: **Dimitrios Mougiakakos, MD, PhD**

Clinical Director, Center for Internal Medicine, Department of Hematology, Oncology and Cell Therapy, University Hospital Magdeburg, Germany

12:40 - 13:00 INTERACTIVE PANEL DISCUSSION

13:00 - 14:00 LUNCH

THE USE OF CELL THERAPIES FOR AUTOIMMUNE DISEASES: CAR-T FROM BIOLOGY TO CLINICAL APPLICATION



DAY 2: October 17, 2025 (continued)

5TH SESSION: TRANSLATION FROM THE DEVELOPERS TO THE CLINICIANS

Chairs:

Ibrahim Yakoub-Agha, MD, PhD

Head of the Hematopoietic Cell Transplantation and Cellular Therapy Unit, Lille University, France

Fermin Sanchez-Guijo, MD, PhD

ISCT Immediate Past Regional Vice-President, Europe
Department of Medicine, University of Salamanca, Department of Hematology, University Hospital Salamanca, Spain

14:00 - 14:20 STATISTICAL CONSIDERATIONS FOR OPTIMAL CAR-T CLINICAL TRIAL DESIGN IN AUTOIMMUNE DISEASES

Speaker: **Lucie Biard, MD, PhD**

Department of Biostatistics, St Louis Hospital, Paris-Cité University, France

14:20 - 14:40 SAFETY OF GENE MODIFIED IMMUNE CELLS: CONSIDERATIONS IN AUTOIMMUNE DISEASE

Speaker: **Bruce Levine, PhD**

Barbara and Edward Netter Professor, University of Pennsylvania, United States

14:40 - 15:05 CELL MANUFACTURING IN THE ACADEMIC SETTING

Speaker: **Manel Juan, MD, PhD**

Head of Immunology Department, Hospital Clinic Barcelona, Spain

15:05 - 15:25 REGULATORY CHALLENGES AND FRAMEWORK FOR CAR-T APPLICATION IN EUROPE (EMA)

Speaker: **Cristina Avendaño, MD, PhD**

Head of Clinical Pharmacology Department, Puerta de Hierro University Hospital, Spain

15:25 - 15:45 HOW TO DEAL WITH EXISTING REGISTRIES REPORTS AND REAL WORLD DATA ANALYSIS?

Speaker: **Raffaella Greco, MD**

Senior Hematologist, Hematology & Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Italy

15:45 - 16:00 COURSE WRAP UP

Dominique Farge, MD, PhD

Fermin Sanchez-Guijo, MD, PhD

Bruce Levine, PhD

PLANNING FACULTY



DOMINIQUE FARGE, MD, PHD

ISCT Regional Vice-President, Europe
Internal Medicine St. Louis Hospital
Paris-Cité University
France



FERMIN SANCHEZ-GUIJO, MD, PHD

ISCT Immediate Past Regional Vice-President, Europe
Department of Medicine University of Salamanca
Department of Hematology University Hospital
Salamanca
Spain



BRUCE LEVINE, PHD

ISCT Past President
Barbara and Edward Netter Professor
University of Pennsylvania
United States



ANDREAS MACKENSEN, MD

Deputy Director CCC Erlangen-EMN
Director of Medical Clinic 5
(Hematology and Internal Oncology)
University Hospital Erlangen
Germany



RAFFAELLA GRECO, MD

EBMT Secretary and Immediate Past Chair
Autoimmune Diseases Working Party Senior
Hematologist Hematology & Bone Marrow
Transplantation IRCCS San Raffaele Hospital
Italy



GEORG SCHETT, MD, PHD

Vice President of Research &
Department Head Internal Medicine
University of Erlangen-Nuremberg
Germany